If replicated in further animal models, investigators say the findings could lay the groundwork for designing therapies that precision-target a specific protein to induce deep sleep.
Apnimed announced positive topline results from the MARIPOSA Phase 2b trial, a study of its lead drug candidate for obstructive sleep apnea.
The clinical trial assessed three doses of IHL-42X at reducing the AHI in patients with OSA, as well as collected safety data.
Sleep Review chief editor Sree Roy is interviewed on episode 18 of SleepTech Talk.
Read More
Expansion of dronabinol’s use into OSA and other therapeutic indications will require new, improved formulations, according to RespireRx.
Read More
Jazz Pharmaceuticals has acquired development and commercialization rights in the United States for Sumitomo’s investigational DSP-0187.
Read More
The acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.
Read More
Harmony Biosciences has initiated a phase 3 trial evaluating the efficacy and safety of pitolisant in adults with idiopathic hypersomnia.
Read MoreSulthiame, a carbonic anhydrase inhibitor, lowered obstructive sleep apnea by more than 20 events/hour, a notable decline for a drug trial.
Read More
World Sleep 2022 attendees learned about results from an experiment about preferred attributes associated with oxybate treatments.
Read More
Topline results from a proof-of-concept randomized, controlled, double-blind, single-dose, crossover study of sleep apnea pill candidates.
Read MoreAvadel Pharmaceuticals plc recently provided a corporate update and announced its financial results for the third quarter ended September 30, 2021.
Read MoreThe primary endpoint will be the frequency of cataplexy attacks. Other symptoms of narcolepsy as well as safety will also be assessed.
Read More“We believe FT218 has tremendous potential to provide clinically meaningful results for people with narcolepsy.”
Read MoreHBS-102 is a MCHR antagonist that has the potential to offer a novel approach to the treatment of narcolepsy including the symptoms of REM sleep dysregulation.
Read MoreThe designation was based, in part, on early phase and preliminary clinical data that indicates Takeda’s investigational oral orexin agonist may demonstrate substantially improved objective and subjective measurements of daytime wakefulness in NT1 patients.
Read MoreAllschwil, Switzerland-based Idorsia Ltd recently announced its financial results for the first half of 2021, at which time its drug daridorexant for the treatment of insomnia under review with United States FDA, EMA, and Swissmedic.
Read MoreApnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, has named David P. White, MD, senior vice president of medical affairs. In this role, White will...
Read More